Citizens analyst Constantine Davides reiterated a Market Outperform rating and $24.00 price target on AMN Healthcare (NYSE: AMN).

The analyst commented, "For AMN Healthcare (AMN, MO, $24 PT), we expect strong 1Q26 results bolstered by the impact of sizable strike-related revenue, and we believe the company is well-positioned to return to its normalized growth algorithm of 4-6% revenue growth and 10-15% EBITDA growth beginning in 2027."

For an analyst ratings summary and ratings history on AMN Healthcare click here. For more ratings news on AMN Healthcare click here.

Shares of AMN Healthcare closed at $20.19 yesterday.